Subscribe To

Price Alert Latest News Economic Calendar News

CRDL / Cardiol Therapeutics enrolls first patient in Phase II CardiolRx study on recurrent pericarditis

Cardiol Therapeutics Inc (TSX:CRDL, NASDAQ:CRDL) said it has enrolled the first patient in its Phase II study evaluating CardiolRx for the treatment of recurrent pericarditis. The company-sponsored Phase II open-label pilot study is investigating the tolerance, safety, and efficacy of CardiolRx in patients with recurrent pericarditis – inflammation of the membrane that surrounds the heart, known as the pericardium. Read More

Demo Live Account See Partner Details

Content Topics

Cardiol

Therapeutics

Enrolls

First

Patient

Phase

Cardiolrx

Recurrent

Pericarditis

Stock

CRDL

Posted: Jan 17 2023, 10:09

Author Name: Proactive Investors

CRDL News

By Proactive Investors
November 1, 2023

Cardiol Therapeutics reaches new milestone in Phase II study for recurrent pericarditis

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) announced it has successfully enrolled over 50% of the targeted number of patients for its Phase II open-

By Proactive Investors
October 10, 2023

Cardiol Therapeutics says study results show positive effects of subcutaneously administered cannabidiol

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) has reported positive study results showing that cannabidiol, the active pharmaceutical ingredient in the

By Zacks Investment Research
September 27, 2023

Here's Why You May Invest in Cardiol Therapeutics (CRDL) Stock

Here we discuss some reasons why investing in Cardiol Therapeutics (CRDL) stock now may turn out to be a prudent move.

By Newsfile Corp
September 26, 2023

Cardiol Therapeutics to Present at Cantor Fitzgerald 2023 Global Healthcare Conference

Toronto, Ontario--(Newsfile Corp. - September 26, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinica

By Zacks Investment Research
August 16, 2023

Cardiol Therapeutics Inc. (CRDL) Upgraded to Buy: Here's What You Should Know

Cardiol Therapeutics Inc. (CRDL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This

By Proactive Investors
May 23, 2023

Cardiol Therapeutics earns higher price target from broker as it ends 1Q with sufficient cash to advance CardioRx candidate

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) has retained a ‘Buy' rating with an increased price target from Canaccord Genuity (TSX:CF, LSE:CF) an

By Proactive Investors
March 29, 2023

Cardiol Therapeutics offers an update on operations as it advances the development of its lead drug candidate CardiolRx

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) Inc CEO David Elsley told investors in a year-end 2022 update on operations that the life sciences compan

By Proactive Investors
March 7, 2023

Cardiol Therapeutics says new study results highlight the cardioprotective effects of cannabidiol

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) said that new study results have demonstrated the cardioprotective effects of pharmaceutically manufactur

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.